Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension
Launched by CHINESE PULMONARY VASCULAR DISEASE RESEARCH GROUP · Sep 30, 2022
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how artificial intelligence (AI) can help in the evaluation and diagnosis of pulmonary hypertension, a serious condition that affects the blood vessels in the lungs. The researchers at Fuwai Hospital in Beijing aim to use AI to analyze different types of medical data from patients who have undergone a specific test called right heart catheterization. By combining this information, they hope to create new tools that can better identify and diagnose pulmonary hypertension, which is crucial for starting effective treatment.
To participate in this trial, individuals must be at least 18 years old and have previously received certain routine health tests, including a chest X-ray and a right heart catheterization at Fuwai Hospital. Unfortunately, those who haven't had these tests or whose test results are not clear enough for analysis will not be eligible. If you join the study, you can expect to contribute to important research that may improve how pulmonary hypertension is diagnosed and treated in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥18 years old
- • Patients previously received chest X-ray, electrocardiography, echocardiography, other routine examinations, and RHC at the Fuwai Hospital, CAMS \& PUMC, Beijing, China
- Exclusion Criteria:
- • Patients without RHC
- • The quality of routine examinations and RHC cannot meet the requirement for further analysis
- • Severe loss of results of routine examinations (chest X-ray, electrocardiography, echocardiography, etc.)
About Chinese Pulmonary Vascular Disease Research Group
The Chinese Pulmonary Vascular Disease Research Group is a leading organization dedicated to advancing the understanding and treatment of pulmonary vascular diseases in China. Comprising a multidisciplinary team of researchers, clinicians, and healthcare professionals, the group focuses on innovative clinical trials and research initiatives aimed at improving patient outcomes and enhancing therapeutic strategies. Through collaboration with academic institutions and healthcare facilities, the group aims to foster groundbreaking discoveries and promote evidence-based practices in the diagnosis and management of pulmonary vascular conditions. Their commitment to advancing medical knowledge and improving patient care positions them as a vital contributor to the field of pulmonary medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Zhihong Liu, MD, PhD
Principal Investigator
Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials